Mason Carrico
Stock Analyst at Stephens
(0.75)
# 4,118
Out of 5,010 analysts
56
Total ratings
37%
Success rate
-3.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Rated: Hold | $30 → $3 | $4.23 | -29.08% | 6 | Aug 18, 2026 | |
| GH Guardant Health | Reiterated: Buy | $63 → $195 | $177.73 | +9.72% | 4 | Aug 4, 2026 | |
| VCYT Veracyte | Reiterated: Buy | $32 → $55 | $46.08 | +19.36% | 5 | Aug 4, 2026 | |
| ATEC Alphatec Holdings | Initiated Coverage: Buy | $15 | $10.37 | +44.65% | 1 | Jul 23, 2026 | |
| IRTC iRhythm Holdings | Initiated Coverage: Buy | $160 | $114.22 | +40.08% | 1 | Jul 22, 2026 | |
| CTKB Cytek Biosciences | Rated: Buy | $4 → $4.75 | $5.76 | -17.53% | 3 | May 13, 2026 | |
| ESTA Establishment Labs Holdings | Rated: Buy | $90 | $63.70 | +41.29% | 1 | Feb 25, 2026 | |
| GKOS Glaukos | Reiterated: Buy | $115 → $145 | $158.55 | -8.55% | 2 | Jan 2, 2026 | |
| PACB Pacific Biosciences of California | Reiterated: Buy | $2.5 → $2 | $1.83 | +9.29% | 3 | Nov 10, 2025 | |
| NEO NeoGenomics | Reiterated: Buy | $18 → $11 | $18.74 | n/a | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $156 → $110 | $272.00 | n/a | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $70 | $18.22 | n/a | 1 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $18 | $64.02 | n/a | 7 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $90.04 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $34.88 | n/a | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $414.52 | n/a | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.1 → $1.25 | $3.38 | n/a | 2 | May 24, 2022 |
Myriad Genetics
Aug 18, 2026
Rated: Hold
Price Target: $30 → $3
Current: $4.23
Upside: -29.08%
Guardant Health
Aug 4, 2026
Reiterated: Buy
Price Target: $63 → $195
Current: $177.73
Upside: +9.72%
Veracyte
Aug 4, 2026
Reiterated: Buy
Price Target: $32 → $55
Current: $46.08
Upside: +19.36%
Alphatec Holdings
Jul 23, 2026
Initiated Coverage: Buy
Price Target: $15
Current: $10.37
Upside: +44.65%
iRhythm Holdings
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $114.22
Upside: +40.08%
Cytek Biosciences
May 13, 2026
Rated: Buy
Price Target: $4 → $4.75
Current: $5.76
Upside: -17.53%
Establishment Labs Holdings
Feb 25, 2026
Rated: Buy
Price Target: $90
Current: $63.70
Upside: +41.29%
Glaukos
Jan 2, 2026
Reiterated: Buy
Price Target: $115 → $145
Current: $158.55
Upside: -8.55%
Pacific Biosciences of California
Nov 10, 2025
Reiterated: Buy
Price Target: $2.5 → $2
Current: $1.83
Upside: +9.29%
NeoGenomics
Sep 2, 2025
Reiterated: Buy
Price Target: $18 → $11
Current: $18.74
Upside: n/a
Aug 4, 2025
Rated: Buy
Price Target: $156 → $110
Current: $272.00
Upside: n/a
Jul 9, 2025
Initiated Coverage: Buy
Price Target: $70
Current: $18.22
Upside: n/a
May 13, 2024
Reiterated: Buy
Price Target: $15 → $18
Current: $64.02
Upside: n/a
May 18, 2023
Reiterated: Buy
Price Target: $65
Current: $90.04
Upside: n/a
May 8, 2023
Reiterated: Buy
Price Target: $41
Current: $34.88
Upside: n/a
Dec 16, 2022
Reiterated: Buy
Price Target: n/a
Current: $414.52
Upside: n/a
May 24, 2022
Downgraded: Hold
Price Target: $3.1 → $1.25
Current: $3.38
Upside: n/a